- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Pfizer Recalls Blood Pressure Drug Accuretic
The recall of Accuretic and generics distributed by Greenstone is a result of the presence of a cancer-causing agent.
Pfizer has recalled Accuretic (quinapril HCI/hydrochlorothiazide) tablets, as well as two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide) because of the presence of a nitrosamine, N-nitroso-quinapril, which can cause cancer.
Pfizer is recalling six lots of Accuretic, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets. Pfizer executives say they have not received any reports of adverse events related to this recall.
Accuretic and its generics are used to treat hypertension.
The lots were distributed nationwide to wholesalers and Distributors in the United States and Puerto Rico from November 2019 to March 2022. A list of the lot numbers can be found here.
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 25th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.
